XXXX in lung transplantation: preliminary results.

@entity1 @entity137 @entity57 @entity3446 @entity177 @entity1781 @entity1011 @entity2258
INTRODUCTION: @entity3446 is a potent immunosuppressive agent with a different mechanism of action and different adverse effects from those of calcineurin inhibitors (CNIs). OBJECTIVE: To analyze our experience with @entity3446 in @entity1 undergoing lung transplantation and heart-lung transplantation in our center. @entity1 AND METHODS: @entity1 were treated with @entity3446 when showing chronic rejection and/or @entity137 associated with the CNI after lung transplantation or heartlung transplantation. @entity1 with chronic rejection were administered @entity3446 in combination with CNIs, whereas the CNIs were eliminated in @entity1 with @entity137 . RESULTS: Since October 2001, 7 @entity1 (4 @entity1 ), of mean age 45+/-15 years, received treatment with @entity3446 (heart-lung transplantation, 2 cases; lung transplantation, 5 cases). The indications were chronic rejection in 4 @entity1 and CMIs @entity137 in 3 @entity1 ( @entity177 in 2 cases and @entity1781 in 1 case). Pulmonary function stabilization was observed in 3 of 4 @entity1 receiving @entity3446 for chronic rejection. In the 3 @entity1 with CNIs @entity137 elimination of these drugs did not result in pulmonary functional deterioration. @entity1 with @entity177 showed an improvement in @entity1011 levels; visual acuity improved in the @entity1 with @entity1781 . We observed 2 infectious complications ( @entity2258 and @entity57 ), which resolved with treatment. CONCLUSION: @entity3446 is an alternative for lung-transplant recipients who develop chronic rejection and/or CNIs @entity137 .
